@article{c53fcbc238974704b145a567a9d2c46a,
title = "Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling",
abstract = "The third annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was held on November 29, 2018, at the American Society of Hematology (ASH) annual meeting. This workshop featured the latest research focused on minimal residual disease (MRD) assessment and immune profiling (IP) in myeloma as well as discussion of the statistical and regulatory issues intrinsic to the development of MRD as a surrogate endpoint. In this report, we provide a summary of the workshop and focus on the integration of MRD and IP assessment into trial design and clinical practice.",
keywords = "CAR T cell, Endpoint, Immune profiling, Minimal residual disease, Multiple myeloma",
author = "Holstein, {Sarah A.} and Zaid Al-Kadhimi and Costa, {Luciano J.} and Theresa Hahn and Parameswaran Hari and Jens Hillengass and Allison Jacob and Munshi, {Nikhil C.} and Stefania Oliva and Pasquini, {Marcelo C.} and Qian Shi and Stadtmauer, {Edward A.} and Waldvogel, {Stephanie L.} and McCarthy, {Philip L.}",
note = "Funding Information: Financial disclosure: Support for the Blood and Marrow Transplant Clinical Trials Network was provided by grant U10HL069294 from the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Support for the PRIMeR ancillary study was provided by NHLBI grant R01HL107213. Funding Information: Financial disclosure: Support for the Blood and Marrow Transplant Clinical Trials Network was provided by grant U10HL069294 from the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Support for the PRIMeR ancillary study was provided by NHLBI grant R01HL107213. Conflict of interest statement: S.A.H. has served on advisory boards for Adaptive Biotechnologies, Celgene, Genentech, Oncopeptides, and Takeda and has served as a consultant for GSK, Celgene, and Sorrento. Z.A. has nothing to disclose. L.J.C. has received research funding from Janssen and Amgen and has received consulting honoraria from Adaptive Biotechnologies, Celgene, Sanofi, and Karyopharm. T.H. has received research funding from Celgene. P.H. has served as a consultant and received research funding from Celgene, Janssen, Bristol-Myers Squibb, Takeda, and Kite. J.H. has received honoraria and travel support from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis, and Takeda and research funding from Celgene and Sanofi. A.J. is an employee and shareholder of Adaptive Biotechnologies. N.C.M. has served as a consultant for Abbvie, Adaptive Biotechnologies, Amgen, Celgene, Janssen, Oncopep, and Takeda and is part owner and stock shareholder of Oncopep. S.O. has received honoraria from Amgen, Celgene, Janssen, and Takeda and has served on advisory board for Adaptive Biotechnologies. M.C.P. has received honoraria from Amgen and Celgene. Q.S. has nothing to disclose. E.A.S. has received honoraria from Amgen, Celgene, Janssen, Novartis, Sanofi, and Takeda. S.W. has nothing to disclose. P.L.M. has received honoraria from Bristol-Myers Squibb, Celgene, Sanofi-Aventis, Takeda, and Binding Site; has received research funding from Celgene; and has served on advisory committees/review panels/board membership for Bristol-Myers Squibb, Celgene, Sanofi-Aventis, Takeda, Binding Site, and Karyopharm. Financial disclosure: See Acknowledgments on page e13. Publisher Copyright: {\textcopyright} 2019 American Society for Transplantation and Cellular Therapy",
year = "2020",
month = jan,
doi = "10.1016/j.bbmt.2019.09.015",
language = "English (US)",
volume = "26",
pages = "e7--e15",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "1",
}